comprehensive -WSS

comprehensive

author：fashion 2025-09-28 23:47:51 - browse：77

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Addressing health care workers' trauma can help fight burnout

focus

WSS

Scrutiny of post

Listen: More tumult at BIO & coercive care for sickle cell patients

Scrutiny of post

What causes rare myocarditis in young men after Covid vaccines?

What it's like to live with paralysis for one psychologist

What it's like to live with paralysis for one psychologist

Wikipedia

comprehensive

explore

What does generative AI mean for health care? We asked experts

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Sports medicine is finally prioritizing gender equality

Liver decline slowed by off

Moonlake's readout produced a cash windfall. Risks remain

STAT Report: Patient voices and perspectives

Psychedelics group wrestles with new pharma identity

Citing H5N1 threat, CDC urges peak flu monitoring this summer

What does generative AI mean for health care? We asked experts

Why patients can’t get everything they want on drug pricing

hotspot

As a primary care physician, here's how I hope to partner with AI

H5N1 bird flu outbreak: Second human case reported, in Michigan

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

H5N1 bird flu outbreak: Second human case reported, in Michigan

Listen: More tumult at BIO & coercive care for sickle cell patients

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

hotspot

focus

leisure time

explore